Low-frequencyKRASmutations are prevalent in lung adenocarcinomas

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones

(2015) Antonio Marchetti et al.   NEOPLASIA

Advances for studying clonal evolution in cancer

(2013) Li Ding et al.   CANCER LETTERS

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

(2013) J. Remon et al.   CANCER TREATMENT REVIEWS

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Roles for KRAS in Pancreatic Tumor Development and Progression

(2013) Marina Pasca di Magliano et al.   GASTROENTEROLOGY

Accurately Identifying Low-Allelic Fraction Variants in Single Samples with Next-Generation Sequencing: Applications in Tumor Subclone Resolution

(2013) Lucy F. Stead et al.   HUMAN MUTATION

KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics

(2013) Markus Rechsteiner et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Somatic alterations as the basis for resistance to targeted therapies

(2013) Brian G Blair et al.   JOURNAL OF PATHOLOGY

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation

(2013) Hiroko Endo et al.   Journal of Thoracic Oncology

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Oncogenic K-Ras requires activation for enhanced activity

(2013) H Huang et al.   ONCOGENE

KRASmutant tumor subpopulations can subvert durable responses to personalized cancer treatments

(2013) Barbara L Parsons et al.   Personalized Medicine

Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide

(2013) Barbara L. Parsons et al.   TOXICOLOGICAL SCIENCES

Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers

(2013) Qingguo Wang et al.   Genome Medicine

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

(2012) Ayodele Ayoola et al.   CANCER INVESTIGATION

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

(2012) Ramaswamy Govindan et al.   CELL

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

ACB-PCR measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues

(2012) Yiying Wang et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer

(2012) Asuka Nakata et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Hotspot oncomutations: implications for personalized cancer treatment

(2012) Meagan B Myers et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

An NF-κB pathway–mediated positive feedback loop amplifies Ras activity to pathological levels in mice

(2012) Jaroslaw Daniluk et al.   JOURNAL OF CLINICAL INVESTIGATION

A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas

(2012) Sylwia Jancik et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

(2012) Jacques Cadranel et al.   Journal of Thoracic Oncology

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

(2012) Vassiliki Papadimitrakopoulou   Journal of Thoracic Oncology

Molecular pathology of lung cancer: key to personalized medicine

(2012) Liang Cheng et al.   MODERN PATHOLOGY

A subset of papillary thyroid carcinomas containKRASmutant subpopulations at levels above normal thyroid

(2012) Meagan B. Myers et al.   MOLECULAR CARCINOGENESIS

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reliable detection of subclonal single-nucleotide variants in tumour cell populations

(2012) Moritz Gerstung et al.   Nature Communications

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Accumulation of K-Ras codon 12 mutations in the F344 rat distal colon following azoxymethane exposure

(2011) Page B. McKinzie et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

(2011) Wolfram Brugger et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

(2011) Kenneth J O'Byrne et al.   LANCET ONCOLOGY

The role of molecular analyses in the era of personalized therapy for advanced NSCLC

(2011) Nichole T. Tanner et al.   LUNG CANCER

p53 codon 271 CGT to CAT mutant fraction does not increase in nasal respiratory and olfactory epithelia of rats exposed to inhaled naphthalene

(2011) Fanxue Meng et al.   MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer

(2011) J. Kondo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ACB-PCR Quantification of K-RASCodon 12 GAT and GTT Mutant Fraction in Colon Tumor and Non-Tumor Tissue

(2010) Barbara L. Parsons et al.   CANCER INVESTIGATION

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2010) Shirin Khambata-Ford et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis

(2010) Janakiraman Subramanian et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

(2009) Chen Mao et al.   LUNG CANCER

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Fetal–juvenile origins of point mutations in the adult human tracheal–bronchial epithelium: Absence of detectable effects of age, gender or smoking status

(2008) Hiroko Sudo et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE